Recombinant poxvirus containing ccl5 and sstr2 genes and preparation method thereof

A pox virus and genetic technology, applied in the field of genetic engineering and tumor biotherapy, to achieve the effects of stable activity, wide host range, and guaranteed safety
CN107164337BActive Publication Date: 2020-08-04FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE
Publication Date
2020-08-04

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a recombinant vaccinia virus rVV-CCL5-SSTR2-Luc+, containing genes CCL5 and SSTR2, constructed by virtue of a homologous recombination method. By utilizing the characteristic that shuttle plasmids containing human target genes CCL5 and SSTR2 and Luciferase reporter genes have same TK side wings with a vaccinia virus WR strain, homologous recombination is carried out in a vaccinia virus susceptible cell BS-C-1 to integrate the target genes to a vaccinia virus genome, so as to construct the recombinant vaccinia virus rVV-CCL5-SSTR2-Luc+. The recombinant vaccinia virus rVV-CCL5-SSTR2-Luc+ is capable of efficiently expressing exogenous genes, meanwhile, CCL5 is matched with highly expressed CCR5 on the surface of a cell CIK, and SSTR2 has the unique advantage on directional induction of octreotide targeted tumor cells, so that the recombinant vaccinia virus is beneficial to clinical expansion and application and is used for treating various tumors.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the fields of genetic engineering and tumor biotherapy, and specifically relates to a recombinant poxvirus containing CCL5 and SSTR2 genes and a preparation method thereof. Background technique

[0002] Oncolytic poxvirus, as a kind of tumor therapy drug and gene therapy carrier, has developed rapidly in recent years. Poxvirus carrying anti-cancer genes can improve its oncolytic effect. Many genetically modified targeted oncolytic poxviruses have entered clinical trials one after another, showing Broad application prospects. Among the oncolytic poxviruses that have entered clinical trials, the Wyeth strain recombinant poxvirus JX-594 inserted into the GM-CSF gene is the earliest recombinant poxvirus to enter clinical trials, and it is also the most studied recombinant poxvirus in clinical trials.

[0003] In the completed Phase I and Phase II clinical trials of JX-594, there was no significant objective curative effect report....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More